W. Bryan Hubbard, CEO of Americans for Ibogaine, joins Secretary Kennedy for a conversation about ibogaine and the emerging future of psychedelic medicine. Drawing on Hubbard’s experience leading the Kentucky Opioid Abatement Advisory Commission and his subsequent advocacy, the discussion explores why ibogaine has attracted growing interest as a potential treatment for opioid addiction, PTSD, and traumatic brain injury.
The conversation also addresses the significant questions that remain around ibogaine, including its known risks and the need for carefully controlled medical research. Hubbard and Secretary Kennedy examine what rigorous scientific study could reveal about the compound’s safety and effectiveness, and what that evidence could ultimately mean for the development of psychedelic-assisted treatments in the United States.